Drug Trial Radar · NCT03564691
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Last checked: Nov 20, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
470
Actual
Start
Jul 11, 2018
Primary completion
Sep 26, 2025
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.
Conditions
- Neoplasms
Interventions
MK-4830Drug
MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
PembrolizumabDrug
Pembrolizumab will be administered at 200 mg IV Q3W.
CarboplatinDrug
Carboplatin will be administered IV Q3W.
PemetrexedDrug
Pemetrexed will be administered IV Q3W.
LenvatinibDrug
Lenvatinib will be administered orally once daily.
PaclitaxelDrug
Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
CisplatinDrug
Cisplatin will be administered IV Q3W.
MK-4830ABiological
MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 21 days)
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 27 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 24 months
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Response Assessment in Neuro-Oncology (RANO) as Assessed by InvestigatorTime frame: Up to approximately 24 months
- ORR per Modified RECIST (mRECIST) 1.1 as Assessed by InvestigatorTime frame: Up to approximately 24 months
Locations
37 sites in 12 countries. Site status is shown where the registry gives one.
University of California at San Francisco ( Site 0004)
San Francisco, California
Henry Ford Health System ( Site 0002)
Detroit, Michigan
Washington University ( Site 0003)
St Louis, Missouri
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)
Hackensack, New Jersey
Laura and Isaac Perlmutter Cancer Center ( Site 0008)
New York, New York
Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00
Columbus, Ohio
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)
San Antonio, Texas
Utah Cancer Specialists ( Site 0011)
Salt Lake City, Utah
Seattle Cancer Care Alliance ( Site 0010)
Seattle, Washington
Liverpool Hospital-Medical Oncology ( Site 0250)
Liverpool, New South Wales, Australia
Princess Alexandra Hospital ( Site 0253)
Brisbane, Queensland, Australia
Juravinski Cancer Centre ( Site 0034)
Hamilton, Ontario, Canada
The Ottawa Hospital ( Site 0031)
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0033)
Toronto, Ontario, Canada
The First Hospital of Jilin University ( Site 0803)
Changchun, Jilin, China
Shanghai Chest Hospital-Oncology department ( Site 0801)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University ( Site 0804)
Chengdu, Sichuan, China
Hôpital Européen Georges Pompidou ( Site 2003)
Paris, Île-de-France Region, France
Centre Oscar Lambret ( Site 2002)
Lille, Nord, France
Centre Hospitalier Universitaire de Poitiers ( Site 2000)
Poitiers, Vienne, France
Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112)
Thessaloniki, Greece
European Interbalkan Medical Center ( Site 0111)
Thessaloniki, Greece
University General Hospital of Heraklion ( Site 0110)
Heraklion, Irakleio, Greece
Rambam Health Care Campus-Oncology Division ( Site 0042)
Haifa, Israel
Rabin Medical Center ( Site 0043)
Petah Tikva, Israel
Chaim Sheba Medical Center. ( Site 0044)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0041)
Tel Aviv, Israel
Japanese Foundation for Cancer Research ( Site 0401)
Tokyo, Japan
National Cancer Center Hospital East ( Site 0400)
Kashiwa, Chiba, Japan
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne ( Site 0151)
Gdansk, Pomeranian Voivodeship, Poland
Wits Clinical Research ( Site 0213)
Johannesburg, Gauteng, South Africa
The Oncology Centre ( Site 0212)
Durban, KwaZulu-Natal, South Africa
Cancercare Rondebosch Oncology ( Site 0210)
Cape Town, Western Cape, South Africa
Severance Hospital Yonsei University Health System ( Site 0300)
Seoul, South Korea
Centro Integral Oncologico Clara Campal START Madrid ( Site 0102)
Madrid, Spain
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101)
L'Hospitalet de Llobregat, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.